Tetrahydrocarbazole derivatives having improved biological...

Details Tetrahydrocarbazole derivatives having improved biological... Tetrahydrocarbazole derivatives having improved biological...

2008-02-14

2011-11-29

Kosack, Joseph (Department: 1626)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Having -c-, wherein x is chalcogen, bonded directly to...

C548S448000

Reexamination Certificate

active

08067456

ABSTRACT:
The present invention provides novel tetrahydrocarbazole derivatives which have improved properties and which can be employed as inhibitors of GPCRs. This results in the possibility of using the novel compounds to treat pathological conditions whose severity depends on the pathobiochemical effect of GPCRs. The compounds of the invention act in particular via an antagonistic inhibition of the LHRH receptor. The invention further provides medicaments which comprise one or more of the novel compounds as active ingredient. The medicaments are suitable in particular to be employed in an oral dosage form for a mammal, in particular a human.

REFERENCES:
patent: 3970757 (1976-07-01), Cross
patent: 5708187 (1998-01-01), Flaugh
patent: 101 64 564 (2003-06-01), None
patent: 0 239 306 (1987-09-01), None
patent: 0 679 642 (1995-11-01), None
patent: 0 603 432 (1998-10-01), None
patent: WO 95/28405 (1995-10-01), None
patent: WO 96/24597 (1996-08-01), None
patent: WO 97/14682 (1997-04-01), None
patent: WO 97/14697 (1997-04-01), None
patent: WO 97/21435 (1997-06-01), None
patent: WO 97/21703 (1997-06-01), None
patent: WO 97/41126 (1997-11-01), None
patent: WO 98/55116 (1998-12-01), None
patent: WO 98/55470 (1998-12-01), None
patent: WO 98/55479 (1998-12-01), None
patent: WO 99/01764 (1999-01-01), None
patent: WO 99/21553 (1999-05-01), None
patent: WO 99/51231 (1999-10-01), None
patent: WO 99/51596 (1999-10-01), None
patent: WO 00/04013 (2000-01-01), None
patent: WO 00/53178 (2000-09-01), None
patent: WO 00/53602 (2000-09-01), None
patent: WO 02/11732 (2002-02-01), None
patent: WO 03/011839 (2003-02-01), None
patent: WO 03/013528 (2003-02-01), None
patent: WO 03/051837 (2003-06-01), None
patent: WO 03/078398 (2003-09-01), None
patent: WO 2005/033099 (2005-04-01), None
Giron, D. J. Therm. Anal. Cal. 2001, 64, pp. 37-60.
Giron, D. J. Therm. Anal. Cal. 2002, 68, pp. 335-357.
B. Rodriquez-Spong et al. Advanced Drug Delivery Reviews, 2004, 56, pp. 241-274.
Souillac, et al., Characterization of Delivery Systems, Differential Scanning Calorimetry, pp. 217-218 (in Encyclopedia of Controlled Drug Delivery, 1999, John Wiley & Sons, pp. 212-227).
Discovery Heatlh (http://health.discovery.com/centers/womens/endometriosis/prevention.html), accessed Mar. 18, 2010.
WebMD (http://women.webmd.com/endometriosis/endometriosis-prevention), Aug. 1, 2007.
MayoClinic.com (http://www.mayoclinic.com/health/endometriosis/DS00289/DSECTION=prevention), Sep. 11, 2008.
Merriam-Webster Online Dictionary entry for “derivative”, (http://www.merriam-webster.com/dictionary/derivative), last accessed May 12, 2010.
Merriam-Webster Online Dictionary entry for “analogue”, (http://www.merriam-webster.com/dictionary/analogue), last accessed May 12, 2010.
Schoneberg et al. Pharmacology & Therapeutics, 2004, 104, 173-206.
Luo et al. Cell, 2009, 136, pp. 823-837.
Herbst, K. Current Opinion in Pharmacology, 2003, 3, 660-666.
Quartara et al. Neuropeptides 1998, 32, 1-49.
Ahlstedt et al. Biochemical Pharmacology 2008, 76, 576-471.
Y.-F. Zhu et al., Expert Opin. Therap. Patents 14(2),187-199 (2004).
Y.-F. Zhu et al., Ann. Rep. Med. Chern. (39), 99-110 (2004).
F.C. Tucci et al., Curro Opin. Drug Discovery & Development 7(6),832-847 (2004).
R.E. Armer, Curr. Med. Chern. 11, 3017-3028 (2004).
M.V. Chengalvala et al., Curro Med. Chem.—Anti-Cancer Agents, 3, 399-410(2003).
N. Cho etal., in J. Med. Chern. 41, 4190-4195 (1998).
S. Sasaki et al., in J. Med. Chern 46, 113-124 (2003).
Z. Guo et al., in J. Med. Chern. 47,1259-1271 (2004).
J. T. Randolph et al., in J. Med. Chern. 47(5), 1085-1097 (2004).
D. J. Davies et al. describe in J. Med Chern. 41, 451-467 (1998).
S. J. Shuttleworth et al., in Bioorg. Med. Chern Lett. 14,3037-3042 (2004).
R Millet et al., describe in Letters in Peptide Science 6,221-223 (1999).
Koppitz et al., THL 46(6),911-914 (2005).
G. Giardina et al., IDrugs 6(8), 758-772 (2003).
V. Leroy et al., Expert Opinion on Investigational Drugs 9(4), 735-746 (2000).
C. Swain et al., Annual Reports in Medicinal Chemistry 34,51-60 (1999).
RM. Navari et al., Cancer Investigation 22(4) 569-576 (2004).
RG. Hill et al., describe in Pain, 523-530 (2003).
A. von Sprecher et al. in IDrugs 1(1), 73-91 (1998).
Y. Fang et al., DDT 8(16), 755-761 (2003).
Y.-F. Zhu et al., Expert Opin. Therap. Patents 14(2), 187-199 (2004).
Y.•F. Zhu et al., Ann. Rep. Med. Chem. (39), 99-110 (2004).
Z. Guo et al., J. Med. Chem. 47, 1259-1271 (2004).
V. Leroy et al., Expert Opinion on Investigational Drugs 9(4), 735-746 (2000).
Ullman's Encyclopedia of Technical Chemistry, vol. 4, (1953)1 39.
Schally et al. Science 173, 1036-1038 (1971).
S.J. Shuttleworth et al., Bioorg. Med. Chem. Lett. 14, 3037-3042 (2004).
S. Sasaki et al., J. Med. Chem. 46, 113-124 (2003).
R.M. Navari et al., Cancer Investigation 22(4) 569-576 (2004).
R.G. Hill et al., Pain, 523-530 (2003).
M.V. Chengalvala et al., Curr. Med. Chem.—Anti-Cancer Agents, 3, 399-410 (2003).
R.E. Armer, Curr. Med. Chem. 11, 3017-3028 (2004).
R. Millet et al., Letters in Peptide Science 6, 221-233 (1999).
R. P. Millar et al., British Med. Bull. 56, 761-772 (2000).
R. E. Felberbaum et al., Mol. Cell. Endocrinology 166, 9-14 (2000).
N. Cho et al. in J. Med. Chem. 41, 4190-4195 (1998).
Mitsunobu et al., J. Am. Chem. Soc. 1972, 94, 679.
Majer et al. Biochem & Biophys. Res. Commun. 1988, 150, 1017.
Koppitz et al.,Tetrahedron Letters 46(6), 911-914 (2005).
K. L. Pierce et al., Nat. Rev. Mol. Cell Biol. 3, 639-650 (2002).
Spiegel AJ et al., Journal of Pharmaceutical Sciences, vol. 52 (1963), 917-927.
J.R. Cashman et al., J. Org. Chem., 1982, 47 (24), 4645-4650.
J. T. Randolph et al., in J. Med. Chem. 47(5), 1085.1097 (2004).
Halmos et al., Proc. Natl. Acad. Sci. USA, 1996, 93, 2398.
H. V. Czetsch-Lindenwald, “Hilfsstoffe für Pharmazie and angrenzende Gebiete”; Pharm. Ind. 2, 1961, 72 et seq.
H. Takahata (J. Org. Chem. 1989, 54, 4812).
F.C. Tucci et al., Curr. Opin. Drug Discovery & Development 7(6), 832-847 (2004).
F. Haviv et al. (Integration of Pharmaceutical Discovery and Development: Case Studies, Chapter 7, ed. Borchardt et al., Plenum Press, New York (1998)).
E. Heuillet et al., J. Neurochem., 60: 868-876 (1993).
Dr. H.P. Fiedler, ,,Lexikon der Hilfsstoffe für Pharmazie, Kosmetik and angrenzende Gebiete, Cantor KG, Aulendorf in Württemberg, 1971.
D. K. Vassilatis et al., PNAS 100(8), 4903-4908 (2003).
D. J. Davies et al. (J. Med. Chem. 41, 451-467 (1998)).
D.M. Ziegler, Biochem. Soc. Trans., 1978, 6(1), 94-96.
D. Aharony et al. Mol. Pharmacol, 44: 356-363 (1993).
Casarett & Doull's “Toxicology, the Basic Science of Poisons”, Chapter 6: Biotransformation of Xenobiotics, C. D. Klaassen Ed., McGraw-Hill 2001.
C. Swain et al., Annual Reports in Medicinal Chemistry 34, 51-60 (1999).
Maki et al., Chem. Pharm. Bull. 1973, 21, 240.
Britten & Lockwood , J. Chem. Soc. Perkin Trans. I 1974, 1824.
A. von Sprecher et al. (IDrugs 1(1), 73-91 (1998)).

Affiliated with

Also associated with

Rating

Tetrahydrocarbazole derivatives having improved biological... does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Tetrahydrocarbazole derivatives having improved biological..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Tetrahydrocarbazole derivatives having improved biological... will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4306596